Showing 17,941 - 17,960 results of 104,446 for search '(( a step decrease ) OR ( 5 ((point decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.86s Refine Results
  1. 17941
  2. 17942

    Stress responses after knockdown of octopamine receptor OAMB and serotonin receptor 5-HT<sub>1A</sub> in IPCs. by Jiangnan Luo (218899)

    Published 2014
    “…In an earlier study it was shown that 5-HT<sub>1A</sub> knockdown decreased starvation resistance <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0099732#pone.0099732-Luo1" target="_blank">[22]</a>. …”
  3. 17943
  4. 17944

    Illustration of controller breakdown of the scheme in Fig 2 when inflows to <i>A</i> exceed the outflows from <i>A</i>. by Peter Ruoff (248735)

    Published 2024
    “…Panel b: <i>E</i> as a function of time for the same <i>k</i><sub>1</sub> steps as in panel a. …”
  5. 17945
  6. 17946

    Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus by Michael A. James (160308)

    Published 2012
    “…<div><p>Cleft Lip and Palate Transmembrane Protein 1-Like (CLPTM1L), resides in a region of chromosome 5 for which copy number gain has been found to be the most frequent genetic event in the early stages of non-small cell lung cancer (NSCLC). …”
  7. 17947

    Table 1_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.xlsx by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
  8. 17948

    Table 1_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.xlsx by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
  9. 17949
  10. 17950
  11. 17951
  12. 17952

    Image_1_Exosomal miR-2276-5p in Plasma Is a Potential Diagnostic and Prognostic Biomarker in Glioma.TIF by Jingxian Sun (6552710)

    Published 2021
    “…</p>Results<p>The exosomal miR-2276-5p in glioma patients had a significantly decreased expression, compared with non-glioma patients (p < 0.01). …”
  13. 17953
  14. 17954

    datasheet1_Krupple-Like Factor 5 is a Potential Therapeutic Target and Prognostic Marker in Epithelial Ovarian Cancer.pdf by Abdul K. Siraj (9723983)

    Published 2020
    “…Identifying novel molecular therapeutic targets is highly needed in the management of EOC. Krupple-like factor 5 (KLF5), a zinc-finger transcriptional factor, is highly expressed in a variety of cancer types. …”
  15. 17955
  16. 17956
  17. 17957

    Table_1_Exosomal miR-2276-5p in Plasma Is a Potential Diagnostic and Prognostic Biomarker in Glioma.doc by Jingxian Sun (6552710)

    Published 2021
    “…</p>Results<p>The exosomal miR-2276-5p in glioma patients had a significantly decreased expression, compared with non-glioma patients (p < 0.01). …”
  18. 17958

    Image 5_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).tif by Ao Shen (127290)

    Published 2025
    “…R-bibliometrix, VOSviewer, and CiteSpace were employed to conduct quantitative analysis and visualize research trends and factors influencing QOL. Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”
  19. 17959
  20. 17960